Synonyms: CC-92480 | CC92480 | compound 4 [PMID: 32130004]
Compound class:
Synthetic organic
Comment: Mezigdomide (CC-92480) is a modulator of the E3 ubiquitin ligase cereblon (CRBN) [1]. It is an immunomodulatory therapeutic candidate for the treatment of multiple myeloma (MM), with an emphasis for lenalidomide-resistant MM. CRBN-mediated degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) induces antitumor and immunomodulatory effects. Mezigdomide's degradion efficiency for IKZF3 is improved compared to pomalidomide and lenalidomide.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
CC-92480 has advanced to clinical evaluations. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03989414 | A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | Phase 1/Phase 2 Interventional | Celgene | ||
NCT05519085 | A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 Interventional | Bristol-Myers Squibb | ||
NCT05552976 | A Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 Interventional | Bristol-Myers Squibb |